Analytical Data
-
Gene name
SCXA
- Application
-
Alternative Names
SCXA；BHLHA41；BHLHA48；SCXA；Basic helix-loop-helix transcription factor scleraxis
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7RTU7
-
Expression Region
1-201aa
-
AA Sequence
MSFATLRPAP PGRYLYPEVS PLSEDEDRGS DSSGSDEKPC RVHAARCGLQ GARRRAGGRR AGGGGPGGRP GREPRQRHTA NARERDRTNS VNTAFTALRT LIPTEPADRK LSKIETLRLA SSYISHLGNV LLAGEACGDG QPCHSGPAFF HAARAGSPPP PPPPPPARDG ENTQPKQICT FCLSNQRKLS KDRDRKTAIR S
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SCXA, or S100 calcium-binding protein A, is a member of the S100 protein family, known for its role in intracellular calcium signaling and regulation of various cellular processes. Research into SCXA has gained momentum due to its significant involvement in various physiological and pathological conditions, including inflammation, cancer, and neurodegenerative diseases. The protein's unique structure, characterized by two EF-hand motifs, allows it to bind calcium ions, influencing its interaction with target proteins and cellular pathways. This makes SCXA not only a crucial biomarker for disease progression but also a potential therapeutic target for drug development. Studies have shown that alterations in SCXA expression levels correlate with disease states, underscoring its importance in diagnostic and prognostic applications. Furthermore, the ability to produce recombinant SCXA proteins through advanced biotechnological methods has opened new avenues for exploring its functional roles and developing potential interventions. Consequently, understanding the molecular mechanisms underpinning SCXA's activity and its interactions can illuminate novel strategies for tackling diseases where SCXA is implicated, thus holding promise for future therapeutic advancements.
